GFP
JNP

Gryphon Financial Partners’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Gryphon Financial Partners’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,000
Closed -$5K – 1055
2017
Q4 		$5K Buy
+1,000
New +$4.86K ﹤0.01% 780

Other funds holding JNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
AG
Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Gryphon Financial Partners's JNP Position: Q1 2018 in Review

Gryphon Financial Partners sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q1 2018, closing a stake of 1,000 shares — an estimated $5K sold.

Gryphon Financial Partners first reported a position in JNP in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 47 funds tracked by Wall St. Rank hold JNP as of Q1 2018.

  • Gryphon Financial Partners reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 1,000 Juniper Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $5K.
  • Gryphon Financial Partners first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Gryphon Financial Partners's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $5K in Q4 2017.
  • 47 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Gryphon Financial Partners's 13F filing for Q1 2018, filed 14 May 2018.